Gene therapy for hemophilia has emerged as a groundbreaking advancement in the treatment of this bleeding disorder, particularly for patients suffering from hemophilia B.This innovative approach, exemplified by the FDA-approved Hemgenix gene therapy, aims to correct the underlying genetic defect that leads to a deficiency in clotting factor IX, a crucial element in blood coagulation.